Fig 1: Construction and validation of the SRGs risk model. (A–C) The survival distribution and expression profiles of VAMP2 and VAMP5 in low- and high-risk patients. (D,E) The Kaplan-Meier plot showing the difference in overall survival (OS) between low- and high-risk groups. (G–I) The time-dependent ROC curve was plotted to assess the SRGs risk model in predicting 1 -, 3 -, and 5-year OS of glioma patients. (J–O) The associations between the risk score and clinicopathological features. O(2): Oligodendroglioma WHO 2 grade; O(3): Oligodendroglioma WHO 3 grade; A(2): Astrocytoma WHO 2 grade; A(3): Astrocytoma WHO 3 grade; A(4): Astrocytoma WHO 4 grade; GBM: Glioblastoma WHO 4 grade. (P–R) Survival analysis between low- and high-risk patients in IDH wild-type gliomas. (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant).